Pharmacogenetics and response to cancer chemotherapy Flashcards

1
Q

What are constitutional polymorphisms?

A

Present since fertilization and in every cell

Less tolerance for variation; contributes to disease development and response to chemotherapy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Name three examples of constitutional polymorphisms.

A
  • Trisomy 13 - Patau syndrome
  • Trisomy 18 - Edward syndrome
  • Trisomy 21 - Down syndrome
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are somatic mutations?

A

Acquired as we age and present in individual cells

More tolerance for variation; contributes to disease development and response to chemotherapy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How do older cancer drugs generally function?

A
  • Target highly proliferating cells
  • Target DNA synthesis
  • Not tailored to specific mutations
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What do newer cancer drugs aim to target?

A
  • Cancer cell-specific features
  • Genomic translocations (e.g., BRC-ABL)
  • Overexpressing oncogenes (e.g., EGFR-TKIs, B-RAF)
  • Phenotypic characteristics (surface protein expression)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What does Dihydropyrimidine Dehydrogenase (DPYD) metabolize?

A

5-fluorouracil

Used for 40 years to treat colorectal, stomach, breast, and pancreatic cancer.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the side effects of 5-fluorouracil?

A
  • Diarrhoea
  • Cardiac toxicity (15-30% of patients)
  • Myelosuppression
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What genetic variants reduce DPYD activity?

A
  • 2846 A>T, Asp949Val
  • 1236 G>A, HAPB3
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the consequence of null activity in DPYD variants?

A

DYPD*2A has a splicing defect resulting in 50% activity (heterozygotes) and no activity (homozygotes)

1679 T>G*13 is another null allele.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the recommendation for individuals with absent DPD activity?

A

No fluorouracil dose has proven safe.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is Irinotecan metabolized by?

A

UGT1A1

Used to treat colorectal and lung cancer.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the side effects of Irinotecan?

A
  • Diarrhoea
  • Neutropenia (15-30% of patients)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What causes Gilbert syndrome?

A

Reduced or absent UGT activity by UGT1A1*28

Linked to hyperbilirubinemia and jaundice.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the prevalence of poor metabolizers in the general population?

A

8-78% depending on ethnic background.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is Cytarabine used for?

A

Backbone therapy for acute myeloid leukaemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the role of Thiopurine methyltransferase (TPMT)?

A

Metabolizes 6-mercaptopurine, azathioprine, and 6-thioguanine

Used for treating various cancers and as immunosuppressants.

17
Q

What are the TMPT polymorphisms?

A
  • TMPT*1 (wild-type)
  • TMPT*2 (G>C at 238 bp)
  • TMPT*3A (480G>A & 719A>G)
  • TMPT*3B (460bp G>A)
  • TMPT*3C (719bp A>G)
  • TMPT*4 (626-1G>A)
18
Q

What is the relationship between TPMT activity and thioguanine nucleotides?

A

Activity is inversely related to TGNs concentration in patient cells.

19
Q

What is the significance of cancer chemotherapy based on tumour cell genotype or phenotype?

A

Allows for targeted therapies that should have little or no effect on non-tumour cells.

20
Q

What mutation is associated with CML?

A

BCR-ABL fusion oncoprotein

Encodes a constitutive ABL kinase activity.

21
Q

What is the gatekeeper residue in the ABL kinase domain?

A

Thr315 (T315)

22
Q

What does the mutation Thr315Ile do?

A

Prevents hydrogen binding between imatinib and the 315 residue.

23
Q

What is Herceptin used for?

A

Monoclonal antibody to HER2 amplified cancer

24
Q

What is the most common mutation in B-RAF?

A

BRAF(V600E)

25
Q

What is the future of pharmacogenetics in cancer therapy focused on?

A
  • Individual variability
  • Genetic profiling
  • Gene expression profiling
  • Protein expression profiling
26
Q

What is the clinical significance of TPMT genotype/phenotype?

A

Dose adjustment based on genotype/phenotype is warranted.